634 related articles for article (PubMed ID: 30833160)
1. Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial.
Li Y; Chu SY; Yue C; Wannemuehler K; Xie S; Zhang F; Wang Y; Zhang Y; Ma R; Li Y; Zuo Z; Rodewald L; Xiao Q; Feng Z; Wang H; An Z
Lancet Infect Dis; 2019 Apr; 19(4):402-409. PubMed ID: 30833160
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of live-attenuated Japanese encephalitis SA 14-14-2 vaccine co-administered with measles vaccine in 9-month-old infants in Sri Lanka.
Wijesinghe PR; Abeysinghe MR; Yoksan S; Yao Y; Zhou B; Zhang L; Yaich M; Neuzil KM; Victor JC
Vaccine; 2014 Aug; 32(37):4751-7. PubMed ID: 24951871
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants.
Gatchalian S; Yao Y; Zhou B; Zhang L; Yoksan S; Kelly K; Neuzil KM; Yaïch M; Jacobson J
Vaccine; 2008 Apr; 26(18):2234-41. PubMed ID: 18394765
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: a phase 4, single-center, randomized controlled trial.
Liu X; Yang W; Zhang C; Wu H; Wang R; Ding Q; Hu Y; Xiong Y; Zhang S; Wang L
Hum Vaccin Immunother; 2021 Dec; 17(12):5348-5354. PubMed ID: 34905446
[TBL] [Abstract][Full Text] [Related]
5. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
Durando P; Esposito S; Bona G; Cuccia M; Desole MG; Ferrera G; Gabutti G; Pellegrino A; Salvini F; Henry O; Povey M; Marchetti F
Vaccine; 2016 Aug; 34(36):4278-84. PubMed ID: 27423382
[TBL] [Abstract][Full Text] [Related]
6. Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan.
Huang LM; Lin TY; Chiu CH; Chiu NC; Chen PY; Yeh SJ; Boaz M; Hutagalung Y; Bouckenooghe A; Feroldi E
Vaccine; 2014 Sep; 32(41):5363-9. PubMed ID: 24631095
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
MMR-161 Study Group
Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
Koren MA; Lin L; Eckels KH; De La Barrera R; Dussupt V; Donofrio G; Sondergaard EL; Mills KT; Robb ML; Lee C; Adedeji O; Keiser PB; Curley JM; Copeland NK; Crowell TA; Hutter JN; Hamer MJ; Valencia-Ruiz A; Darden J; Peel S; Amare MF; Mebrahtu T; Costanzo M; Krebs SJ; Gromowski GD; Jarman RG; Thomas SJ; Michael NL; Modjarrad K
Lancet Infect Dis; 2023 Oct; 23(10):1175-1185. PubMed ID: 37390836
[TBL] [Abstract][Full Text] [Related]
10. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
Nolan T; McIntyre P; Roberton D; Descamps D
Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
[TBL] [Abstract][Full Text] [Related]
11. Long-term Immunogenicity of Measles Vaccine: An Italian Retrospective Cohort Study.
Bianchi FP; Stefanizzi P; De Nitto S; Larocca AMV; Germinario C; Tafuri S
J Infect Dis; 2020 Feb; 221(5):721-728. PubMed ID: 31580436
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
Sood A; Mitra M; Joshi HA; Nayak US; Siddaiah P; Babu TR; Mahapatro S; Sanmukhani J; Gupta G; Mittal R; Glueck R
Hum Vaccin Immunother; 2017 Jul; 13(7):1523-1530. PubMed ID: 28362563
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
Abu-Elyazeed R; Jennings W; Severance R; Noss M; Caplanusi A; Povey M; Henry O
Hum Vaccin Immunother; 2018; 14(11):2624-2631. PubMed ID: 29902133
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.
Clarke E; Saidu Y; Adetifa JU; Adigweme I; Hydara MB; Bashorun AO; Moneke-Anyanwoke N; Umesi A; Roberts E; Cham PM; Okoye ME; Brown KE; Niedrig M; Chowdhury PR; Clemens R; Bandyopadhyay AS; Mueller J; Jeffries DJ; Kampmann B
Lancet Glob Health; 2016 Aug; 4(8):e534-47. PubMed ID: 27364568
[TBL] [Abstract][Full Text] [Related]
16. Prospective Study of Live Attenuated Vaccines for Patients with Nephrotic Syndrome Receiving Immunosuppressive Agents.
Kamei K; Miyairi I; Ishikura K; Ogura M; Shoji K; Funaki T; Ito R; Arai K; Abe J; Kawai T; Onodera M; Ito S
J Pediatr; 2018 May; 196():217-222.e1. PubMed ID: 29499990
[TBL] [Abstract][Full Text] [Related]
17. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.
Nakayama T; Eda M; Hirano M; Goto W
Hum Vaccin Immunother; 2019; 15(5):1139-1144. PubMed ID: 30724658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
